{"organizations": [], "uuid": "622ed5663e04e53c0d86d856e158df90cc45da6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-alerts-of-neural-tube-birth/brief-u-s-fda-alerts-of-neural-tube-birth-defects-cases-reported-in-babies-born-to-women-treated-with-dolutegravir-idUSFWN1SP0TY", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Alerts Of Neural Tube Birth Defects Cases Reported In Babies Born To Women Treated With Dolutegravir", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.987, "site_type": "news", "published": "2018-05-19T00:51:00.000+03:00", "replies_count": 0, "uuid": "622ed5663e04e53c0d86d856e158df90cc45da6b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-alerts-of-neural-tube-birth/brief-u-s-fda-alerts-of-neural-tube-birth-defects-cases-reported-in-babies-born-to-women-treated-with-dolutegravir-idUSFWN1SP0TY", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Alerts Of Neural Tube Birth Defects Cases Reported In Babies Born To Women Treated With Dolutegravir", "locations": [], "entities": {"persons": [{"name": "dolutegravir", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "dolutegravir", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - U.S. Food and Drug Administration:\n* U.S. FDA SAYS ALERTING PUBLIC TO SERIOUS CASES OF NEURAL TUBE BIRTH DEFECTS REPORTED IN BABIES BORN TO WOMEN TREATED WITH DOLUTEGRAVIR USED TO TREAT HIV\n* SAYS PRELIM RESULTS FROM ONGOING STUDY FOUND WOMEN GETTING DOLUTEGRAVIR AT TIME OF BECOMING PREGNANT/EARLY IN FIRST TRIMESTER APPEAR AT HIGHER RISK FOR DEFECTS\n* SAYS TO DATE, IN STUDY, THERE ARE NO REPORTED CASES OF BABIES BORN WITH NEURAL TUBE DEFECTS TO WOMEN STARTING DOLUTEGRAVIR LATER IN PREGNANCY Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-19T00:51:00.000+03:00", "crawled": "2018-05-19T15:26:31.016+03:00", "highlightTitle": ""}